Xenograft Model Antitumor Assays
"Xenograft Model Antitumor Assays" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
| Descriptor ID |
D023041
|
| MeSH Number(s) |
E05.337.550.200.900 E05.624.850
|
| Concept/Terms |
Xenograft Model Antitumor Assays- Xenograft Model Antitumor Assays
- Tumor Xenograft Assay
- Xenograft Antitumor Assays
- Antitumor Assay, Xenograft
- Antitumor Assays, Xenograft
- Assay, Xenograft Antitumor
- Assays, Xenograft Antitumor
- Xenograft Antitumor Assay
- Antitumor Assays, Xenograft Model
|
Below are MeSH descriptors whose meaning is more general than "Xenograft Model Antitumor Assays".
Below are MeSH descriptors whose meaning is more specific than "Xenograft Model Antitumor Assays".
This graph shows the total number of publications written about "Xenograft Model Antitumor Assays" by people in this website by year, and whether "Xenograft Model Antitumor Assays" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 2 | 2 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 0 | 3 | 3 |
| 2006 | 0 | 3 | 3 |
| 2007 | 1 | 1 | 2 |
| 2008 | 0 | 8 | 8 |
| 2009 | 1 | 3 | 4 |
| 2010 | 1 | 4 | 5 |
| 2011 | 0 | 9 | 9 |
| 2012 | 0 | 5 | 5 |
| 2013 | 1 | 9 | 10 |
| 2014 | 0 | 10 | 10 |
| 2015 | 1 | 11 | 12 |
| 2016 | 0 | 10 | 10 |
| 2017 | 0 | 12 | 12 |
| 2018 | 0 | 13 | 13 |
| 2019 | 2 | 11 | 13 |
| 2020 | 0 | 8 | 8 |
| 2021 | 1 | 4 | 5 |
| 2022 | 0 | 2 | 2 |
| 2024 | 0 | 7 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Xenograft Model Antitumor Assays" by people in Profiles.
-
Targeting Oncogenic RET Kinase by Simultaneously Inhibiting Kinase Activity and Degrading the Protein. J Med Chem. 2025 Jan 09; 68(1):81-94.
-
Oklahoma nitrone-007 is an effective anticancer therapeutic agent targeting inflammatory and immune metabolism pathways in endometrial cancer. J Pharmacol Exp Ther. 2025 Jan; 392(1):100004.
-
Development of Novel Indole-Based Covalent Inhibitors of TEAD as Potential Antiliver Cancer Agents. J Med Chem. 2024 Sep 26; 67(18):16270-16295.
-
A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples. Cancer Res Commun. 2024 09 01; 4(9):2384-2398.
-
The Novel ATR Inhibitor M1774 Induces Replication Protein Overexpression and Broad Synergy with DNA-targeted Anticancer Drugs. Mol Cancer Ther. 2024 Jul 02; 23(7):911-923.
-
Noninvasive therapy of brain cancer using a unique systemic delivery methodology with a cancer terminator virus. J Cell Physiol. 2024 Aug; 239(8):e31302.
-
Deciphering a GPCR-lncrna-miRNA nexus: Identification of an aberrant therapeutic target in ovarian cancer. Cancer Lett. 2024 Jun 01; 591:216891.
-
Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates. Oncotarget. 2022; 13:553-575.
-
Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer. Sci Rep. 2022 01 19; 12(1):974.
-
WNK1 Enhances Migration and Invasion in Breast Cancer Models. Mol Cancer Ther. 2021 10; 20(10):1800-1808.